TITLE

Human Papillomavirus (HPV) Vaccination Coverage among Rhode Island Adolescents, 2008-2016

AUTHOR(S)
KIM, HYUN (HANNA); WASHBURN, TRICIA; MARCEAU, KATHY; DUGGAN-BALL, SUE; RAYMOND, PATRICIA
PUB. DATE
March 2018
SOURCE
Rhode Island Medical Journal;Mar2018, Vol. 101 Issue 2, p49
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the report from Centers for Disease Control and Prevention (CDC) regarding the Human Papillomavirus (HPV) Vaccination to protect against cancers and genital warts caused by HPV infections. It mentions up-to-date (UTD) doses of HPV vaccination coverage rates among Rhode Island and healthcare providers (HCPs) play a critical role in improving HPV vaccination rates. It also mentions HPV vaccine to the school immunization requirements to improve HPV vaccination.
ACCESSION #
110346987

 

Related Articles

  • Monitoring the coverage and impact of human papillomavirus vaccine -- report of WHO meeting, November 2009.  // Weekly Epidemiological Record;6/18/2010, Vol. 85 Issue 25, p237 

    The article reports on the coverage and impact monitoring of the human pappilomavirus vaccine (HPV). It states that monitoring vaccine coverage of HPV is valuable in the evaluation of vaccine programs and vaccine impact. It also cites several possible biological resultants for the monitoring...

  • Quadrivalent Human Papillomavirus Vaccine. Barr, Eliav; Tamms, Gretchen // Clinical Infectious Diseases;9/1/2007, Vol. 45 Issue 5, p609 

    The lifetime risk of human papillomavirus (HPV) infection exceeds 50%. HPV infection causes >550,000 cases of cervical and anogenital cancer worldwide annually. Infection also causes precancerous lesions and genital warts. HPV types 16 and 18 cause ~70% of HPV-related cancers, and HPV types 6...

  • GARDASIL: WHAT YOU NEED TO KNOW ABOUT THE HPV Vaccine.  // Network Magazine of the Canadian Women's Health Network;Spring/Summer2007, Vol. 9 Issue 3/4, p14 

    The article offers information about the Gardasil, a human papillomavirus (HPV) vaccine approved for use in Canada and the U.S. It is noted that this specific vaccine prevents infection from HPV types 6 and 11, which cause genital warts, and HPV types 16 and 18, which cause cancer. However, the...

  • Drivers and barriers to acceptance of human-papillomavirus vaccination among young women: a qualitative and quantitative study. Mortensen, Gitte Lee // BMC Public Health;2010, Vol. 10 Issue 1, p1 

    Background: Human papillomavirus (HPV) is a necessary cause of cervical dysplasia and cancer, and of genital warts. Few studies have examined attitudes to HPV vaccination since the introduction of HPV vaccines. We aimed to investigate the reasons for young women's acceptance or rejection of the...

  • HPV vaccine given to males prevents genital warts.  // Contemporary Pediatrics;Mar2011, Vol. 28 Issue 3, p10 

    No abstract available.

  • Addressing Health Inequalities in the Delivery of the Human Papillomavirus Vaccination Programme: Examining the Role of the School Nurse. Boyce, Tammy; Holmes, Alison; Fielding, Richard // PLoS ONE;Sep2012, Vol. 7 Issue 9, Special section p1 

    Background: HPV immunisation of adolescent girls is expected to have a significant impact in the reduction of cervical cancer. UK The HPV immunisation programme is primarily delivered by school nurses. We examine the role of school nurses in delivering the HPV immunisation programme and their...

  • HPV vaccine and its recommendations, 2007. Zimmerman, Richard Kent // Journal of Family Practice;Feb2007 Supplement, Vol. 56 Issue 2, pS1 

    Quadrivalent human papillomavirus vaccine against the viral types most likely to cause cervical cancer (types 16 and 18) and genital warts (types 6 and 11) has been licensed in the United States. The vaccine is 95% to 100% efficacious against cervical intraepithelial neoplasia and adenocarcinoma...

  • El estado del arte en las infecciones producidas por el virus del papiloma humano. Reina, Julio César; Muñoz, Nubia; Sanchez, Gloria Inés // Colombia Medica;abr-jun2008, Vol. 39 Issue 2, p196 

    Anogenital human papillomavirus infection is the most frequent sexually transmitted disease. Around one hundred genotypes have been identified in humans, and 40 infect the genitalia and anal regions. Fifteen genotypes, classified as highrisk HPVs, are the necessary cause of cervical cancer and...

  • Ignoble Poxes. BURCH, DRUIN // Natural History;Mar2014, Vol. 122 Issue 2, p12 

    The author discusses human papilomavirus (HPV) vaccinations, with information on a study published by the "British Medical Journal" (BMJ) in April 2013 regarding the effectiveness of Australia's national human papilomavirus (HPV) vaccination programme. Topics include cancers related to HPV, the...

  • Estimation of the impact of genital warts on health-related quality of life. Woodhall, S.; Ramsey, T.; Cai, C.; Crouch, S.; Jit, M.; Birks, Y.; Edmunds, W. J.; Newton, R.; Lacey, C. J. N. // Sexually Transmitted Infections;Jun2008, Vol. 84 Issue 3, p161 

    Objectives: One of the two new human papillomavirus (HPV) vaccines protects against HPV types 6 and 11, which cause over 95% of genital warts, in addition to protecting against HPV types 16 and 18. In anticipation of HPV vaccine implementation, the impact of genital warts on health-related...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics